| Dr Joel Thomas Mcfarland, MD | |
|
209 Martin Luther King Jr Way, Tacoma, WA 98405-4265 | |
| (253) 596-3300 | |
| (253) 596-3301 |
| Full Name | Dr Joel Thomas Mcfarland |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 24 Years |
| Location | 209 Martin Luther King Jr Way, Tacoma, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003889932 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | C166930 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of Washington | 9032022579 | 1480 |
News Archive
Only two per cent of paediatric drug trials reported that they had established independent safety monitoring committees that can help lead to the early detection of adverse drug reactions, according to a major review in the April issue of Acta Paediatrica.
A new study by a University of Warwick researcher has demonstrated that researchers trying to model a range of processes could use the power and capabilities of a particular XBox chip as a much cheaper alternative to other forms of parallel processing hardware.
Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial.
Levels of a small non-coding RNA molecule called let-7 appear to define different stages of cancer better than some of the "classical" markers for tumor progression, researchers from the University of Chicago report in the June 25, 2007, early online edition of the Proceedings of the National Academy of Sciences.
A series of experiments at EPFL provide conclusive evidence that the brain uses a single mechanism (supramodality) to estimate confidence in different senses such as audition, touch, or vision. The study is published in the Journal of Neuroscience.
› Verified 4 days ago
| Entity Name | Kaiser Foundation Health Plan Of Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396810701 PECOS PAC ID: 9032022579 Enrollment ID: O20031112000454 |
News Archive
Only two per cent of paediatric drug trials reported that they had established independent safety monitoring committees that can help lead to the early detection of adverse drug reactions, according to a major review in the April issue of Acta Paediatrica.
A new study by a University of Warwick researcher has demonstrated that researchers trying to model a range of processes could use the power and capabilities of a particular XBox chip as a much cheaper alternative to other forms of parallel processing hardware.
Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial.
Levels of a small non-coding RNA molecule called let-7 appear to define different stages of cancer better than some of the "classical" markers for tumor progression, researchers from the University of Chicago report in the June 25, 2007, early online edition of the Proceedings of the National Academy of Sciences.
A series of experiments at EPFL provide conclusive evidence that the brain uses a single mechanism (supramodality) to estimate confidence in different senses such as audition, touch, or vision. The study is published in the Journal of Neuroscience.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joel Thomas Mcfarland, MD 8933 Activity Rd, San Diego, CA 92126-4427 Ph: (858) 653-6130 | Dr Joel Thomas Mcfarland, MD 209 Martin Luther King Jr Way, Tacoma, WA 98405-4265 Ph: (253) 596-3300 |
News Archive
Only two per cent of paediatric drug trials reported that they had established independent safety monitoring committees that can help lead to the early detection of adverse drug reactions, according to a major review in the April issue of Acta Paediatrica.
A new study by a University of Warwick researcher has demonstrated that researchers trying to model a range of processes could use the power and capabilities of a particular XBox chip as a much cheaper alternative to other forms of parallel processing hardware.
Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial.
Levels of a small non-coding RNA molecule called let-7 appear to define different stages of cancer better than some of the "classical" markers for tumor progression, researchers from the University of Chicago report in the June 25, 2007, early online edition of the Proceedings of the National Academy of Sciences.
A series of experiments at EPFL provide conclusive evidence that the brain uses a single mechanism (supramodality) to estimate confidence in different senses such as audition, touch, or vision. The study is published in the Journal of Neuroscience.
› Verified 4 days ago
Dr. Yuyao Zhang, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1304 Fawcett Ave Ste 100, Tacoma, WA 98402 Phone: 253-761-4201 Fax: 253-761-4201 | |
Mark Ranier Dalisay, Radiology Medicare: Not Enrolled in Medicare Practice Location: 7520 S I St, Tacoma, WA 98408 Phone: 702-305-1889 | |
Dr. Jana Lynn Fahmy, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1304 Fawcett Ave Ste 100, Tacoma, WA 98402 Phone: 253-761-4200 Fax: 253-761-4201 | |
Dr. Scott Randall Henneman, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1304 Fawcett Ave Ste 100, Tacoma, WA 98402 Phone: 253-761-4200 Fax: 253-761-4201 | |
Dr. Mark Gerard O'callaghan, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 209 Martin Luther King Jr Way, Tacoma, WA 98405 Phone: 253-596-3300 | |
Peter Alan Ory, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1304 Fawcett Ave, Suite 100, Tacoma, WA 98402 Phone: 253-680-3372 Fax: 253-383-3553 |